These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25794248)

  • 1. Factors influencing utilization of the primary prevention implantable defibrillator.
    Zhang L; Narayanan K; Chugh H; Shiota T; Zheng ZJ; Chugh SS
    PLoS One; 2015; 10(3):e0121515. PubMed ID: 25794248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community.
    Narayanan K; Reinier K; Uy-Evanado A; Teodorescu C; Chugh H; Marijon E; Gunson K; Jui J; Chugh SS
    Circulation; 2013 Oct; 128(16):1733-8. PubMed ID: 24048201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
    Mezu U; Adelstein E; Jain S; Saba S
    Am J Cardiol; 2011 Sep; 108(5):718-22. PubMed ID: 21640321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and physician determinants of implantable cardioverter defibrillator use in the heart failure population.
    Chae SH; Koelling TM
    Congest Heart Fail; 2010; 16(4):141-6. PubMed ID: 20662865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators.
    Sadarmin PP; Wong KC; Rajappan K; Bashir Y; Betts TR
    Europace; 2014 Nov; 16(11):1575-9. PubMed ID: 24668515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era.
    Groeneveld PW; Matta MA; Suh JJ; Yang F; Shea JA
    Pacing Clin Electrophysiol; 2007 Apr; 30(4):463-71. PubMed ID: 17437568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?
    Daugherty SL; Peterson PN; Wang Y; Curtis JP; Heidenreich PA; Lindenfeld J; Vidaillet HJ; Masoudi FA;
    Am Heart J; 2009 Aug; 158(2):224-9. PubMed ID: 19619698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Factors predisposing to the reprogramming of implantable cardioverter-defibrillators and the causes of changes in pharmacotherapy in patients with dilated cardiomyopathy for primary prevention of sudden cardiac death].
    Pudło J; Liszniański P; Senderek T; Lelakowska-Pieła M; Lelakowski J; Nowak J
    Pol Merkur Lekarski; 2015 Aug; 39(230):86-90. PubMed ID: 26319381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?
    Liang JJ; Hodge DO; Mehta RA; Russo AM; Prasad A; Cha YM
    Europace; 2014 Dec; 16(12):1759-66. PubMed ID: 25100756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients?
    Siu CW; Pong V; Ho HH; Liu S; Lau CP; Li SW; Tse HF
    J Cardiovasc Electrophysiol; 2010 Mar; 21(3):231-5. PubMed ID: 19804551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
    Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
    Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
    Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
    J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low referral rate for prophylactic implantation of cardioverter-defibrillators in a tertiary care medical center.
    Bradfield J; Warner A; Bersohn MM
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S194-7. PubMed ID: 19250092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of Cardiac Magnetic Resonance Imaging Versus Echocardiography-Guided Patient Selection for Primary Prevention Implantable Cardioverter Defibrillator Therapy.
    Rijnierse MT; van der Lingen AL; Weiland MT; de Haan S; Nijveldt R; Beek AM; van Rossum AC; Allaart CP
    Am J Cardiol; 2015 Aug; 116(3):406-12. PubMed ID: 26050137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter defibrillator therapy activation for high risk patients with relatively well preserved left ventricular ejection fraction. Does it really work?
    Gatzoulis KA; Tsiachris D; Dilaveris P; Archontakis S; Arsenos P; Vouliotis A; Sideris S; Trantalis G; Kartsagoulis E; Kallikazaros I; Stefanadis C
    Int J Cardiol; 2013 Aug; 167(4):1360-5. PubMed ID: 22534047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.